Singapore markets closed

Sanofi (SNYNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
112.50+10.35 (+10.13%)
At close: 11:40AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close102.15
Bid0.00 x 0
Ask0.00 x 0
Day's range112.42 - 112.50
52-week range91.55 - 114.80
Avg. volume12,109
Market cap140.474B
Beta (5Y monthly)0.36
PE ratio (TTM)20.06
EPS (TTM)5.61
Earnings dateN/A
Forward dividend & yield3.52 (3.13%)
Ex-dividend date06 May 2022
1y target estN/A
  • Motley Fool

    This Safe Stock Is Dirt Cheap -- and It's Beating the Market

    The giant French drugmaker Sanofi (NASDAQ: SNY) isn't exactly an obvious candidate for a stock that's likely to beat the market, but its total return of around 8.5% this year is undoubtedly superior to the market's losses of more than 15.4%. Let's take a peek at Sanofi to appreciate why it could be a great pick for the more conservative portion of your holdings. Sanofi sells Dupixent, which treats atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.

  • Financial Times

    Unilever and Sanofi pile on pressure over 2035 EU petrol ban

    A cross-sector coalition of companies including Unilever, Zurich, Sanofi and Uber have urged the EU to ban the sale of new petrol and diesel vehicles from 2035, piling pressure on the auto industry ahead of a crunch vote. In a public letter to be sent to MEPs and ministers on Tuesday, the group says such a decision would “set in motion an urgently needed systemic transformation and make Europe a global leader in a key industry”. Volkswagen’s chief executive Herbert Diess has also directly criticised German utility companies in the past, including coal-fired power producers RWE and Uniper, for not doing enough to decarbonise energy.

  • Reuters

    Sanofi ordered to compensate French family for epilepsy drug side effects

    A French court has ordered Sanofi to pay more than 400,000 euros ($416,440) in damages to a family whose child suffered from a form of autism caused by its epilepsy drug Valproate, saying the drugmaker failed to inform about known side effects. The link, alongside physical malformation, had also been recognised in a landmark class action ruling in January, which could potentially lead to hundreds of millions of euros in compensation, though Sanofi said it would file an appeal. The latest ruling, made last week and seen by Reuters on Saturday, states that Sanofi must have known the risk that the drug, if taken by pregnant women, could cause malformations and "neuro-behavioural disorders" in children, which should have been mentioned in its attached leaflet.